Epigenetics advancing personalized nanomedicine in cancer therapy

Advanced Drug Delivery Reviews

Volumn 64, Issue 13, 2012, Pages 1532-1543

  Liu, Shujun ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

5hmC; 5mC; ABC; AML; ATP; BCR; Biomarkers; BRCA1; CBF ; CBP; CML; CREB; DNMT; DOX; Drug delivery; EGFR; Epigenetics; ER; ErbB2; ETO; FHIT; FLT3; GSTP1; HAT; HDAC; HDMT; HER2; HGP; HMT; IDH; IL 3; MDS; MiRs; MOZ; MRI; MZ; Nanomedicine; Nanoparticles; Nanotechnology; Personalized medicine; Personalized nanomedicine; PI3K; PZLF; RAR ; RASSF1A; SAM; SMMHC; SNPs; Targeted therapy; TET; TSGs; UTRs; VMRs; WWOX

Indexed keywords

5HMC; 5MC; ABC; AML; BCR; BRCA1; CBP; CREB; DNMT; DOX; EGFR; EPIGENETICS; ERBB2; ETO; FHIT; FLT3; GSTP1; HAT; HDAC; HDMT; HER2; HGP; HMT; IDH; IL-3; MDS; MIRS; MOZ; MZ; PERSONALIZED MEDICINES; PI3K; PZLF; RASSF1A; SAM; SMMHC; SNPS; TARGETED THERAPY; TET; TSGS; UTRS; VMRS; WWOX;

ADENOSINETRIPHOSPHATE; BIOMARKERS; DRUG DELIVERY; EMITTER COUPLED LOGIC CIRCUITS; ERBIUM; HEALTH CARE; MAGNETIC RESONANCE IMAGING; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOTECHNOLOGY; ONCOLOGY;

DIAGNOSIS;

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DOXORUBICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; NANOPARTICLE; ROMIDEPSIN; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER THERAPY; CARDIOTOXICITY; CHROMOSOME ABERRATION; CIRCULATING TUMOR CELL; CPG ISLAND; DNA METHYLATION; DRUG DELIVERY SYSTEM; ENCAPSULATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; NANOMEDICINE; NANOTECHNOLOGY; ONCOGENE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

EPIGENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; NEOPLASMS;

EID: 84867658694     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.08.004     Document Type: Review

References (169)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
2. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., Heine-Suner D., Cigudosa J.C., Urioste M., Benitez J., Boix-Chornet M., Sanchez-Aguilera A., Ling C., Carlsson E., Poulsen P., Vaag A., Stephan Z., Spector T.D., Wu Y.Z., Plass C., Esteller M. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10604-10609.
3. Madhavan S., Gusev Y., Harris M., Tanenbaum D.M., Gauba R., Bhuvaneshwar K., Shinohara A., Rosso K., Carabet L.A., Song L., Riggins R.B., Dakshanamurthy S., Wang Y., Byers S.W., Clarke R., Weiner L.M. G-DOC: a systems medicine platform for personalized oncology. Neoplasia 2011, 13:771-783.
4. Potti A., Schilsky R.L., Nevins J.R. Refocusing the war on cancer: the critical role of personalized treatment. Sci. Transl. Med. 2010, 2.
5. Clayton T.A., Baker D., Lindon J.C., Everett J.R., Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14728-14733.
6. Hvistendahl M. My microbiome and me. Science 2012, 336:1248-1250.
7. Haiser H.J., Turnbaugh P.J. Is it time for a metagenomic basis of therapeutics?. Science 2012, 336:1253-1255.
8. Maitland M.L., Schilsky R.L. Clinical trials in the era of personalized oncology. CA Cancer J. Clin. 2011, 61:365-381.
9. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin. Pharmacol. Ther. 2007, 81:164-169.
10. Janku F., Garrido-Laguna I., Petruzelka L.B., Stewart D.J., Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:1601-1612.
11. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
12. Russnes H.G., Navin N., Hicks J., Borresen-Dale A.L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Invest. 2011, 121:3810-3818.
13. Blaxter M. Genetics. Revealing the dark matter of the genome. Science 2010, 330:1758-1759.
14. Ashworth A., Lord C.J., Reis-Filho J.S. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
15. Hansen K.D., Timp W., Bravo H.C., Sabunciyan S., Langmead B., McDonald O.G., Wen B., Wu H., Liu Y., Diep D., Briem E., Zhang K., Irizarry R.A., Feinberg A.P. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 2011, 43:768-775.
16. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., MacConaill L., Lee J.C., Nicoletti R., Hatton C., Goyette M., Girard L., Majmudar K., Ziaugra L., Wong K.K., Gabriel S., Beroukhim R., Peyton M., Barretina J., Dutt A., Emery C., Greulich H., Shah K., Sasaki H., Gazdar A., Minna J., Armstrong S.A., Mellinghoff I.K., Hodi F.S., Dranoff G., Mischel P.S., Cloughesy T.F., Nelson S.F., Liau L.M., Mertz K., Rubin M.A., Moch H., Loda M., Catalona W., Fletcher J., Signoretti S., Kaye F., Anderson K.C., Demetri G.D., Dummer R., Wagner S., Herlyn M., Sellers W.R., Meyerson M., Garraway L.A. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 2007, 39:347-351.
17. Stephens P.J., McBride D.J., Lin M.L., Varela I., Pleasance E.D., Simpson J.T., Stebbings L.A., Leroy C., Edkins S., Mudie L.J., Greenman C.D., Jia M., Latimer C., Teague J.W., Lau K.W., Burton J., Quail M.A., Swerdlow H., Churcher C., Natrajan R., Sieuwerts A.M., Martens J.W., Silver D.P., Langerod A., Russnes H.E., Foekens J.A., Reis-Filho J.S., van 't Veer L., Richardson A.L., Borresen-Dale A.L., Campbell P.J., Futreal P.A., Stratton M.R. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010.
18. Liu S., Shen T., Huynh L., Klisovic M.I., Rush L.J., Ford J.L., Yu J., Becknell B., Li Y., Liu C., Vukosavljevic T., Whitman S.P., Chang K.S., Byrd J.C., Perrotti D., Plass C., Marcucci G. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res. 2005, 65:1277-1284.
19. Guo J.Q., Lian J.Y., Xian Y.M., Lee M.S., Deisseroth A.B., Stass S.A., Champlin R.E., Talpaz M., Wang J.Y., Arlinghaus R.B. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 1994, 83:3629-3637.
20. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M.A., Iyer V., Chen T.T., Huang F., Decillis A.P., Sawyers C.L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354:2531-2541.
21. Klein C.J., Botuyan M.V., Wu Y., Ward C.J., Nicholson G.A., Hammans S., Hojo K., Yamanishi H., Karpf A.R., Wallace D.C., Simon M., Lander C., Boardman L.A., Cunningham J.M., Smith G.E., Litchy W.J., Boes B., Atkinson E.J., Middha S., PJ B.D., Parisi J.E., Mer G., Smith D.I., Dyck P.J. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat. Genet. 2011, 43:595-600.
22. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., Kandoth C., Payton J.E., Baty J., Welch J., Harris C.C., Lichti C.F., Townsend R.R., Fulton R.S., Dooling D.J., Koboldt D.C., Schmidt H., Zhang Q., Osborne J.R., Lin L., O'Laughlin M., McMichael J.F., Delehaunty K.D., McGrath S.D., Fulton L.A., Magrini V.J., Vickery T.L., Hundal J., Cook L.L., Conyers J.J., Swift G.W., Reed J.P., Alldredge P.A., Wylie T., Walker J., Kalicki J., Watson M.A., Heath S., Shannon W.D., Varghese N., Nagarajan R., Westervelt P., Tomasson M.H., Link D.C., Graubert T.A., DiPersio J.F., Mardis E.R., Wilson R.K. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 2010, 363:2424-2433.
23. Kanai Y., Ushijima S., Nakanishi Y., Sakamoto M., Hirohashi S. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. Cancer Lett. 2003, 192:75-82.
24. Liu S., Wu L.C., Pang J., Santhanam R., Schwind S., Wu Y.Z., Hickey C.J., Yu J., Becker H., Maharry K., Radmacher M.D., Li C., Whitman S.P., Mishra A., Stauffer N., Eiring A.M., Briesewitz R., Baiocchi R.A., Chan K.K., Paschka P., Caligiuri M.A., Byrd J.C., Croce C.M., Bloomfield C.D., Perrotti D., Garzon R., Marcucci G. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010, 17:333-347.
25. Kerr K.M. Personalized medicine for lung cancer: new challenges for pathology. Histopathology 2012, 60:531-546. 10.1111/j.1365-2559.2011.03854.x.
26. Swanton C., Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br. J. Cancer 2009, 100:1517-1522.
27. Oakman C., Santarpia L., Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat. Rev. Clin. Oncol. 2010, 7:725-732.
28. Perez E.A. Breast cancer management: opportunities and barriers to an individualized approach. Oncologist 2011, 16(Suppl. 1):20-22.
29. Laing R.E., Hess P., Shen Y., Wang J., Hu S.X. The role and impact of SNPs in pharmacogenomics and personalized medicine. Curr. Drug Metab. 2011, 12:460-486.
30. Landi M.T., Chatterjee N., Caporaso N.E., Rotunno M., Albanes D., Thun M., Wheeler W., Rosenberger A., Bickeboller H., Risch A., Wang Y., Gaborieau V., Thorgeirsson T., Gudbjartsson D., Sulem P., Spitz M.R., Wichmann H.E., Rafnar T., Stefansson K., Houlston R.S., Brennan P. GPC5 rs2352028 variant and risk of lung cancer in never smokers. Lancet Oncol. 2010, 11:714-716. (author reply 716).
31. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 2007, 116:496-526.
32. Breving K., Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. Int. J. Biochem. Cell Biol. 2010, 42:1316-1329.
33. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 2010, 10:389-402.
34. McBride C.M., Alford S.H., Reid R.J., Larson E.B., Baxevanis A.D., Brody L.C. Putting science over supposition in the arena of personalized genomics. Nat. Genet. 2008, 40:939-942.
35. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
36. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., Banham A.H., Pezzella F., Boultwood J., Wainscoat J.S., Hatton C.S., Harris A.L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
37. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
38. Hui A., How C., Ito E., Liu F.F. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 2011, 11:500.
39. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
40. Sakamoto J.H., van de Ven A.L., Godin B., Blanco E., Serda R.E., Grattoni A., Ziemys A., Bouamrani A., Hu T., Ranganathan S.I., De Rosa E., Martinez J.O., Smid C.A., Buchanan R.M., Lee S.Y., Srinivasan S., Landry M., Meyn A., Tasciotti E., Liu X., Decuzzi P., Ferrari M. Enabling individualized therapy through nanotechnology. Pharmacol. Res. 2010, 62:57-89.
41. Feinberg A.P., Irizarry R.A., Fradin D., Aryee M.J., Murakami P., Aspelund T., Eiriksdottir G., Harris T.B., Launer L., Gudnason V., Fallin M.D. Personalized epigenomic signatures that are stable over time and covary with body mass index. Sci. Transl. Med. 2010, 2.
42. Andersen J.N., Sathyanarayanan S., Di Bacco A., Chi A., Zhang T., Chen A.H., Dolinski B., Kraus M., Roberts B., Arthur W., Klinghoffer R.A., Gargano D., Li L., Feldman I., Lynch B., Rush J., Hendrickson R.C., Blume-Jensen P., Paweletz C.P. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci. Transl. Med. 2010, 2.
43. Leary R.J., Kinde I., Diehl F., Schmidt K., Clouser C., Duncan C., Antipova A., Lee C., McKernan K., De La Vega F.M., Kinzler K.W., Vogelstein B., Diaz L.A., Velculescu V.E. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2010, 2.
44. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
45. Jimeno A., Messersmith W.A., Hirsch F.R., Franklin W.A., Eckhardt S.G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 2009, 27:1130-1136.
46. Mardis E.R. The $1,000 genome, the $100,000 analysis?. Genome Med. 2010, 2:84.
47. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2002, 2:331-341.
48. Liotta L., Petricoin E. Molecular profiling of human cancer. Nat. Rev. Genet. 2000, 1:48-56.
49. Petricoin E.F., Zoon K.C., Kohn E.C., Barrett J.C., Liotta L.A. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 2002, 1:683-695.
50. Jain K.K. Advances in the field of nanooncology. BMC Med. 2010, 8:83.
51. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:311-330.
52. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., Jacks T., Anderson D.G. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 2012, 12:39-50.
53. Boukany P.E., Morss A., Liao W.C., Henslee B., Jung H., Zhang X., Yu B., Wang X., Wu Y., Li L., Gao K., Hu X., Zhao X., Hemminger O., Lu W., Lafyatis G.P., Lee L.J. Nanochannel electroporation delivers precise amounts of biomolecules into living cells. Nat. Nanotechnol. 2011, 6:747-754.
54. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
55. Arvizo R.R., Rana S., Miranda O.R., Bhattacharya R., Rotello V.M., Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine 2011, 7:580-587.
56. Arvizo R.R., Miranda O.R., Thompson M.A., Pabelick C.M., Bhattacharya R., Robertson J.D., Rotello V.M., Prakash Y.S., Mukherjee P. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010, 10:2543-2548.
57. Gaster R.S., Hall D.A., Nielsen C.H., Osterfeld S.J., Yu H., Mach K.E., Wilson R.J., Murmann B., Liao J.C., Gambhir S.S., Wang S.X. Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat. Med. 2009, 15:1327-1332.
58. Galanzha E.I., Shashkov E.V., Kelly T., Kim J.W., Yang L., Zharov V.P. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat. Nanotechnol. 2009, 4:855-860.
59. Sanhai W.R., Sakamoto J.H., Canady R., Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3:242-244.
60. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
61. Shvedova A.A., Castranova V., Kisin E.R., Schwegler-Berry D., Murray A.R., Gandelsman V.Z., Maynard A., Baron P. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J. Toxicol. Environ. Health A 2003, 66:1909-1926.
62. Lam C.W., James J.T., McCluskey R., Hunter R.L. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol. Sci. 2004, 77:126-134.
63. Kipen H.M., Laskin D.L. Smaller is not always better: nanotechnology yields nanotoxicology. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L696-L697.
64. Radomski A., Jurasz P., Alonso-Escolano D., Drews M., Morandi M., Malinski T., Radomski M.W. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 2005, 146:882-893.
65. Chen Z., Meng H., Xing G., Chen C., Zhao Y., Jia G., Wang T., Yuan H., Ye C., Zhao F., Chai Z., Zhu C., Fang X., Ma B., Wan L. Acute toxicological effects of copper nanoparticles in vivo. Toxicol. Lett. 2006, 163:109-120.
66. Hussain S.M., Javorina A.K., Schrand A.M., Duhart H.M., Ali S.F., Schlager J.J. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol. Sci. 2006, 92:456-463.
67. Jain K.K. Applications of nanobiotechnology in clinical diagnostics. Clin. Chem. 2007, 53:2002-2009.
68. Debbage P. Targeted drugs and nanomedicine: present and future. Curr. Pharm. Des. 2009, 15:153-172.
69. Emerich D.F., Thanos C.G. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol. Eng. 2006, 23:171-184.
70. Caruthers S.D., Winter P.M., Wickline S.A., Lanza G.M. Targeted magnetic resonance imaging contrast agents. Methods Mol. Med. 2006, 124:387-400.
71. Schmieder A.H., Winter P.M., Caruthers S.D., Harris T.D., Williams T.A., Allen J.S., Lacy E.K., Zhang H., Scott M.J., Hu G., Robertson J.D., Wickline S.A., Lanza G.M. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 2005, 53:621-627.
72. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
73. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
74. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
75. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37:217-222.
76. Abdolmaleky H.M., Zhou J.R., Thiagalingam S., Smith C.L. Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics. Pharmacogenomics 2008, 9:1809-1823.
77. Anway M.D., Cupp A.S., Uzumcu M., Skinner M.K. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005, 308:1466-1469.
78. Heijmans B.T., Tobi E.W., Stein A.D., Putter H., Blauw G.J., Susser E.S., Slagboom P.E., Lumey L.H. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17046-17049.
79. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonte B., Szyf M., Turecki G., Meaney M.J. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12:342-348.
80. Bock C. Epigenetic biomarker development. Epigenomics 2009, 1:99-110.
81. Wolff G.L., Kodell R.L., Moore S.R., Cooney C.A. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB J. 1998, 12:949-957.
82. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., Dymov S., Szyf M., Meaney M.J. Epigenetic programming by maternal behavior. Nat. Neurosci. 2004, 7:847-854.
83. Boks M.P., Derks E.M., Weisenberger D.J., Strengman E., Janson E., Sommer I.E., Kahn R.S., Ophoff R.A. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS One 2009, 4:e6767.
84. Christensen B.C., Houseman E.A., Marsit C.J., Zheng S., Wrensch M.R., Wiemels J.L., Nelson H.H., Karagas M.R., Padbury J.F., Bueno R., Sugarbaker D.J., Yeh R.F., Wiencke J.K., Kelsey K.T. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009, 5:e1000602.
85. Schreiber S.L., Bernstein B.E. Signaling network model of chromatin. Cell 2002, 111:771-778.
86. Turner B.M. Defining an epigenetic code. Nat. Cell Biol. 2007, 9:2-6.
87. Bjornsson H.T., Sigurdsson M.I., Fallin M.D., Irizarry R.A., Aspelund T., Cui H., Yu W., Rongione M.A., Ekstrom T.J., Harris T.B., Launer L.J., Eiriksdottir G., Leppert M.F., Sapienza C., Gudnason V., Feinberg A.P. Intra-individual change over time in DNA methylation with familial clustering. JAMA 2008, 299:2877-2883.
88. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 128:707-719.
89. Berger S.L., Kouzarides T., Shiekhattar R., Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009, 23:781-783.
90. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., Havelange V., Volinia S., Blum W., Rush L.J., Perrotti D., Andreeff M., Bloomfield C.D., Byrd J.C., Chan K., Wu L.C., Croce C.M., Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
91. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., Liu S., Alder H., Costinean S., Fernandez-Cymering C., Volinia S., Guler G., Morrison C.D., Chan K.K., Marcucci G., Calin G.A., Huebner K., Croce C.M. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15805-15810.
92. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
93. Allis C.D., Berger S.L., Cote J., Dent S., Jenuwien T., Kouzarides T., Pillus L., Reinberg D., Shi Y., Shiekhattar R., Shilatifard A., Workman J., Zhang Y. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131:633-636.
94. Mohn F., Schubeler D. Genetics and epigenetics: stability and plasticity during cellular differentiation. Trends Genet. 2009, 25:129-136.
95. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009, 277:8-21.
96. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5:981-989.
97. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009, 280:168-176.
98. Liu K., Wang Y.F., Cantemir C., Muller M.T. Endogenous assays of DNA methyltransferases: evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo. Mol. Cell. Biol. 2003, 23:2709-2719.
99. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
100. Ting A.H., Jair K.W., Suzuki H., Yen R.W., Baylin S.B., Schuebel K.E. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat. Genet. 2004, 36:582-584.
101. Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W., Baylin S.B., Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
102. Tsumura A., Hayakawa T., Kumaki Y., Takebayashi S., Sakaue M., Matsuoka C., Shimotohno K., Ishikawa F., Li E., Ueda H.R., Nakayama J., Okano M. Maintenance of self-renewal ability of mouse embryonic stem cells in the absence of DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b. Genes Cells 2006, 11:805-814.
103. Robert M.F., Morin S., Beaulieu N., Gauthier F., Chute I.C., Barsalou A., MacLeod A.R. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 2003, 33:61-65.
104. Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A., Rappsilber J., Helin K. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011, 473:343-348.
105. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
106. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
107. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z., Wolniak K., Peeters J.K., Liu W., Choe S.E., Fantin V.R., Paietta E., Lowenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J., Thompson C.B., Levine R.L., Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
108. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
109. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
110. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
111. Mizuno S., Chijiwa T., Okamura T., Akashi K., Fukumaki Y., Niho Y., Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97:1172-1179.
112. Girault I., Tozlu S., Lidereau R., Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 2003, 9:4415-4422.
113. Goelz S.E., Vogelstein B., Hamilton S.R., Feinberg A.P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228:187-190.
114. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
115. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004, 4:707-717.
116. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
117. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
118. Iliopoulos D., Guler G., Han S.Y., Johnston D., Druck T., McCorkell K.A., Palazzo J., McCue P.A., Baffa R., Huebner K. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005, 24:1625-1633.
119. Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A., Zanesi N., Yendamuri S., Han S.Y., Amadori D., Huebner K., Croce C.M. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15611-15616.
120. Suzuki M., Sunaga N., Shames D.S., Toyooka S., Gazdar A.F., Minna J.D. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res. 2004, 64:3137-3143.
121. Melki J.R., Vincent P.C., Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999, 59:3730-3740.
122. Bjornsson H.T., Fallin M.D., Feinberg A.P. An integrated epigenetic and genetic approach to common human disease. Trends Genet. 2004, 20:350-358.
123. Mateo Leach I., van der Harst P., de Boer R.A. Pharmacoepigenetics in heart failure. Curr. Heart Fail. Rep. 2010, 7:83-90.
124. Papait R., Condorelli G. Epigenetics in heart failure. Ann. N. Y. Acad. Sci. 2010, 1188:159-164.
125. Richardson B. Primer: epigenetics of autoimmunity. Nat. Clin. Pract. Rheumatol. 2007, 3:521-527.
126. Hamm C.A., Costa F.F. The impact of epigenomics on future drug design and new therapies. Drug Discov. Today 2011, 16:626-635.
127. Petronis A. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol. Psychiatry 2004, 55:965-970.
128. Goldring M.B., Marcu K.B. Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis. Trends Mol. Med. 2012, 18:109-118.
129. Barter M.J., Bui C., Young D.A. Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAs. Osteoarthritis Cartilage 2012, 20:339-349.
130. Gomez A., Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin. Pharmacol. Ther. 2009, 85:426-430.
131. Jirtle R.L., Skinner M.K. Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 2007, 8:253-262.
132. Bailey V.J., Easwaran H., Zhang Y., Griffiths E., Belinsky S.A., Herman J.G., Baylin S.B., Carraway H.E., Wang T.H. MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Res. 2009, 19:1455-1461.
133. Li M., Chen W.D., Papadopoulos N., Goodman S.N., Bjerregaard N.C., Laurberg S., Levin B., Juhl H., Arber N., Moinova H., Durkee K., Schmidt K., He Y., Diehl F., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W., Markowitz S.D., Vogelstein B. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 2009, 27:858-863.
134. Talens R.P., Boomsma D.I., Tobi E.W., Kremer D., Jukema J.W., Willemsen G., Putter H., Slagboom P.E., Heijmans B.T. Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology. FASEB J. 2010, 24:3135-3144.
135. Curtis R.E., Boice J.D., Moloney W.C., Ries L.G., Flannery J.T. Leukemia following chemotherapy for breast cancer. Cancer Res. 1990, 50:2741-2746.
136. Carli P.M., Sgro C., Parchin-Geneste N., Isambert N., Mugneret F., Girodon F., Maynadie M. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000, 14:1014-1017.
137. Valentini C.G., Fianchi L., Voso M.T., Caira M., Leone G., Pagano L. Incidence of acute myeloid leukemia after breast cancer. Mediterr. J. Hematol. Infect. Dis. 2011, 3:e2011069.
138. Smits K.M., Cleven A.H., Weijenberg M.P., Hughes L.A., Herman J.G., de Bruine A.P., van Engeland M. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics 2008, 9:1903-1916.
139. Manolopoulos V.G., Ragia G., Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011, 12:1161-1191.
140. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
141. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
142. Shivapurkar N., Gazdar A.F. DNA methylation based biomarkers in non-invasive cancer screening. Curr. Mol. Med. 2010, 10:123-132.
143. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999, 59:67-70.
144. Chen W.D., Han Z.J., Skoletsky J., Olson J., Sah J., Myeroff L., Platzer P., Lu S., Dawson D., Willis J., Pretlow T.P., Lutterbaugh J., Kasturi L., Willson J.K., Rao J.S., Shuber A., Markowitz S.D. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 2005, 97:1124-1132.
145. Hoque M.O., Begum S., Topaloglu O., Chatterjee A., Rosenbaum E., Van Criekinge W., Westra W.H., Schoenberg M., Zahurak M., Goodman S.N., Sidransky D. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl. Cancer Inst. 2006, 98:996-1004.
146. Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., Haney J., Kennedy T.C., Hirsch F.R., Miller Y., Franklin W.A., Herman J.G., Baylin S.B., Bunn P.A., Byers T. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006, 66:3338-3344.
147. Lee W.H., Morton R.A., Epstein J.I., Brooks J.D., Campbell P.A., Bova G.S., Hsieh W.S., Isaacs W.B., Nelson W.G. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11733-11737.
148. Hoque M.O., Topaloglu O., Begum S., Henrique R., Rosenbaum E., Van Criekinge W., Westra W.H., Sidransky D. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 2005, 23:6569-6575.
149. Richiardi L., Fiano V., Vizzini L., De Marco L., Delsedime L., Akre O., Tos A.G., Merletti F. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J. Clin. Oncol. 2009, 27:3161-3168.
150. Ioshikhes I.P., Zhang M.Q. Large-scale human promoter mapping using CpG islands. Nat. Genet. 2000, 26:61-63.
151. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomaki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su Huang H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000, 24:132-138.
152. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
153. Kelly T.K., De Carvalho D.D., Jones P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 2010, 28:1069-1078.
154. Oki Y., Issa J.P. Epigenetic mechanisms in AML-a target for therapy. Cancer Treat. Res. 2010, 145:19-40.
155. Herman J.G., Jen J., Merlo A., Baylin S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996, 56:722-727.
156. Issa J.P., Zehnbauer B.A., Civin C.I., Collector M.I., Sharkis S.J., Davidson N.E., Kaufmann S.H., Baylin S.B. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 1996, 56:973-977.
157. Issa J.P., Kantarjian H.M., Kirkpatrick P. Azacitidine. Nat. Rev. Drug Discov. 2005, 4:275-276.
158. Blum W., Schwind S., Tarighat S.S., Geyer S., Eisfeld A.K., Whitman S., Walker A., Klisovic R., Byrd J.C., Santhanam R., Wang H., Curfman J.P., Devine S.M., Jacob S., Garr C., Kefauver C., Perrotti D., Chan K.K., Bloomfield C.D., Caligiuri M.A., Grever M.R., Garzon R., Marcucci G. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012, 119:6025-6031.
159. Marks P.A. Epigenetic targeted anti-cancer drugs: an unfolding story. Oncology (Williston Park) 2011, 25:231, 235.
160. Boumber Y., Issa J.P. Epigenetics in cancer: what's the future?. Oncology (Williston Park) 2011, 25:220-226. (228).
161. Issa J.P., Kantarjian H.M. Targeting DNA methylation. Clin. Cancer Res. 2009, 15:3938-3946.
162. Yoo C.B., Jeong S., Egger G., Liang G., Phiasivongsa P., Tang C., Redkar S., Jones P.A. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007, 67:6400-6408.
163. Muller C.I., Ruter B., Koeffler H.P., Lubbert M. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr. Pharm. Biotechnol. 2006, 7:315-321.
164. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., Jacob S.T. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 2005, 25:4727-4741.
165. Liu S., Liu Z., Xie Z., Pang J., Yu J., Lehmann E., Huynh L., Vukosavljevic T., Takeki M., Klisovic R.B., Baiocchi R.A., Blum W., Porcu P., Garzon R., Byrd J.C., Perrotti D., Caligiuri M.A., Chan K.K., Wu L.C., Marcucci G. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008, 111:2364-2373.
166. Flasshove M., Strumberg D., Ayscue L., Mitchell B.S., Tirier C., Heit W., Seeber S., Schutte J. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994, 8:780-785.
167. Stegmann A.P., Honders M.W., Hagemeijer A., Hoebee B., Willemze R., Landegent J.E. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann. Hematol. 1995, 71:41-47.
168. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci. Transl. Med. 2010, 2:14ps12.
169. Szyf M. Toward a discipline of pharmacoepigenomics. Curr. Pharmacogenomics 2004, 2:357-377.